Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carotid Artery Diseases | 7 | 2020 | 102 | 1.810 |
Why?
|
| Dyslipidemias | 4 | 2017 | 109 | 1.550 |
Why?
|
| Hypolipidemic Agents | 6 | 2018 | 99 | 1.410 |
Why?
|
| Lipids | 4 | 2014 | 285 | 1.380 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 395 | 1.240 |
Why?
|
| Atherosclerosis | 5 | 2016 | 267 | 0.960 |
Why?
|
| Carotid Arteries | 4 | 2018 | 136 | 0.910 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 395 | 0.910 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2020 | 40 | 0.710 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2018 | 62 | 0.610 |
Why?
|
| HIV Infections | 2 | 2020 | 974 | 0.600 |
Why?
|
| Cause of Death | 1 | 2020 | 279 | 0.590 |
Why?
|
| Heart Sounds | 2 | 2025 | 2 | 0.590 |
Why?
|
| American Heart Association | 1 | 2017 | 110 | 0.510 |
Why?
|
| Primary Prevention | 1 | 2017 | 87 | 0.500 |
Why?
|
| Cyclin D1 | 1 | 2016 | 85 | 0.480 |
Why?
|
| Myocardial Contraction | 1 | 2017 | 253 | 0.480 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 157 | 0.460 |
Why?
|
| Pericardium | 1 | 2016 | 84 | 0.460 |
Why?
|
| Guideline Adherence | 1 | 2017 | 245 | 0.460 |
Why?
|
| Foramen Ovale, Patent | 1 | 2015 | 24 | 0.450 |
Why?
|
| Anticholesteremic Agents | 2 | 2016 | 153 | 0.440 |
Why?
|
| Carotid Stenosis | 2 | 2012 | 115 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1347 | 0.410 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2012 | 3642 | 0.400 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 778 | 0.400 |
Why?
|
| Adipose Tissue | 1 | 2016 | 272 | 0.400 |
Why?
|
| Azetidines | 2 | 2016 | 37 | 0.400 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 190 | 0.400 |
Why?
|
| Thrombosis | 2 | 2015 | 326 | 0.390 |
Why?
|
| Heart Diseases | 1 | 2015 | 318 | 0.370 |
Why?
|
| Coronary Stenosis | 1 | 2012 | 39 | 0.370 |
Why?
|
| Jejunum | 1 | 2012 | 80 | 0.370 |
Why?
|
| Intestinal Absorption | 1 | 2012 | 126 | 0.360 |
Why?
|
| Heart Ventricles | 1 | 2017 | 826 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 647 | 0.350 |
Why?
|
| Hypertension | 1 | 2017 | 775 | 0.340 |
Why?
|
| MicroRNAs | 1 | 2016 | 591 | 0.340 |
Why?
|
| Cholesterol, HDL | 4 | 2017 | 173 | 0.340 |
Why?
|
| Disease Progression | 4 | 2020 | 1561 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1096 | 0.320 |
Why?
|
| Cholesterol, LDL | 6 | 2018 | 246 | 0.290 |
Why?
|
| Blood Glucose | 1 | 2012 | 873 | 0.290 |
Why?
|
| Middle Aged | 14 | 2020 | 28299 | 0.260 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2006 | 4 | 0.250 |
Why?
|
| Trypanosoma cruzi | 1 | 2006 | 8 | 0.250 |
Why?
|
| Humans | 25 | 2025 | 95992 | 0.250 |
Why?
|
| Lipoproteins, HDL | 1 | 2006 | 93 | 0.240 |
Why?
|
| Heart Auscultation | 1 | 2025 | 3 | 0.230 |
Why?
|
| Male | 16 | 2025 | 45792 | 0.220 |
Why?
|
| Niacin | 4 | 2016 | 37 | 0.200 |
Why?
|
| Cardiology | 1 | 2025 | 134 | 0.200 |
Why?
|
| Risk Factors | 4 | 2020 | 5992 | 0.200 |
Why?
|
| Treatment Outcome | 6 | 2018 | 9228 | 0.190 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 277 | 0.190 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 365 | 0.180 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3922 | 0.180 |
Why?
|
| Biomarkers | 4 | 2018 | 1931 | 0.170 |
Why?
|
| Incidence | 3 | 2015 | 1723 | 0.170 |
Why?
|
| Heart Transplantation | 1 | 2006 | 816 | 0.160 |
Why?
|
| Cell Proliferation | 2 | 2016 | 1753 | 0.160 |
Why?
|
| Time Factors | 4 | 2018 | 5593 | 0.160 |
Why?
|
| Students, Medical | 1 | 2025 | 455 | 0.150 |
Why?
|
| Female | 12 | 2025 | 49980 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2025 | 858 | 0.150 |
Why?
|
| Coronary Angiography | 2 | 2012 | 262 | 0.140 |
Why?
|
| Lipoprotein(a) | 1 | 2018 | 30 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 905 | 0.130 |
Why?
|
| Compliance | 1 | 2017 | 21 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 897 | 0.130 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 43 | 0.130 |
Why?
|
| Chest Pain | 1 | 2017 | 49 | 0.130 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2016 | 14 | 0.120 |
Why?
|
| Antigens, Nuclear | 1 | 2016 | 28 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 438 | 0.120 |
Why?
|
| Heart Failure | 1 | 2006 | 1438 | 0.120 |
Why?
|
| Melanocytes | 1 | 2016 | 60 | 0.120 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 100 | 0.120 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 27 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2016 | 279 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2025 | 1134 | 0.120 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2015 | 18 | 0.110 |
Why?
|
| Adult | 8 | 2018 | 28636 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1018 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 1166 | 0.110 |
Why?
|
| Cell Cycle | 1 | 2016 | 516 | 0.110 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2015 | 84 | 0.100 |
Why?
|
| Cisplatin | 1 | 2016 | 599 | 0.100 |
Why?
|
| Heptanoic Acids | 2 | 2011 | 72 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1176 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 516 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 307 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2020 | 3115 | 0.100 |
Why?
|
| Pyrroles | 2 | 2011 | 172 | 0.100 |
Why?
|
| Apoptosis | 2 | 2016 | 1756 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 2498 | 0.090 |
Why?
|
| Ezetimibe | 1 | 2012 | 37 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 789 | 0.090 |
Why?
|
| Simvastatin | 2 | 2016 | 106 | 0.090 |
Why?
|
| Melanoma | 1 | 2016 | 495 | 0.090 |
Why?
|
| Cell Line | 1 | 2016 | 2536 | 0.090 |
Why?
|
| Smoking | 1 | 2015 | 651 | 0.090 |
Why?
|
| Global Health | 1 | 2013 | 214 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2776 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1962 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1959 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2016 | 1729 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 28 | 0.060 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 70 | 0.060 |
Why?
|
| Aged | 3 | 2018 | 20927 | 0.060 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 255 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2385 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1792 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2006 | 173 | 0.050 |
Why?
|
| United States | 1 | 2017 | 7785 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2025 | 246 | 0.050 |
Why?
|
| Animals | 3 | 2015 | 28901 | 0.050 |
Why?
|
| Contrast Media | 1 | 2006 | 1097 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1819 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 1880 | 0.040 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 220 | 0.030 |
Why?
|
| Colestipol | 1 | 2016 | 3 | 0.030 |
Why?
|
| Lovastatin | 1 | 2016 | 28 | 0.030 |
Why?
|
| Luciferases | 1 | 2016 | 130 | 0.030 |
Why?
|
| Hyperlipoproteinemias | 1 | 2015 | 7 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 142 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2015 | 27 | 0.030 |
Why?
|
| Triglycerides | 1 | 2016 | 235 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 67 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 326 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2015 | 54 | 0.030 |
Why?
|
| Streptokinase | 1 | 1995 | 12 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 299 | 0.030 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 1995 | 13 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 303 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 150 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 436 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 796 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 385 | 0.030 |
Why?
|
| Adipocytes | 1 | 2015 | 169 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 1995 | 107 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 890 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 750 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 562 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 477 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 1167 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 996 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2015 | 272 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 1995 | 261 | 0.020 |
Why?
|
| Idaho | 1 | 2011 | 9 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2011 | 36 | 0.020 |
Why?
|
| Washington | 1 | 2011 | 51 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 212 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 555 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2928 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 824 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1231 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2011 | 4690 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 235 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2088 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 1021 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 1425 | 0.020 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2007 | 11 | 0.020 |
Why?
|
| Allylamine | 1 | 2007 | 14 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7224 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1205 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2474 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 3581 | 0.010 |
Why?
|
| Brain | 1 | 2015 | 2479 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 4374 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1995 | 2603 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 12525 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2885 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1995 | 311 | 0.010 |
Why?
|